{
    "clinical_study": {
        "@rank": "87261", 
        "arm_group": [
            {
                "arm_group_label": "Placebo then resveratrol", 
                "arm_group_type": "Experimental", 
                "description": "Participants in this arm (decided according to Latin square) first received placebo and then resveratrol, on seperate days, with a 7-14 day wash-out period between visits."
            }, 
            {
                "arm_group_label": "Resveratrol then placebo", 
                "arm_group_type": "Experimental", 
                "description": "Participants in this arm (decided according to Latin square) first received resveratrol and then placebo, on seperate days, with a 7-14 day wash-out period between visits"
            }
        ], 
        "brief_summary": {
            "textblock": "This study investigated the potentially cognitive enhancing effects of 500mg\n      trans-resveratrol in healthy, young humans."
        }, 
        "brief_title": "Cognitive Effects of 500mg Trans-resveratrol", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Cognitive Performance", 
            "Mood"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18-35yrs, healthy.\n\n        Exclusion Criteria:\n\n          -  Drug/alcohol abuse, taking prescription medication (apart from contraception) or\n             herbal supplements, having food intolerances or allergies, having suffered a\n             head-injury or neurological/neuro-developmental disorder, uncorrected sight problems,\n             pregnant or seeking to become so, excessive caffeine use (e.g. more than 6 cups of\n             coffee per day)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794351", 
            "org_study_id": "22P5"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Placebo then resveratrol", 
                    "Resveratrol then placebo"
                ], 
                "description": "In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.", 
                "intervention_name": "Trans-resveratrol", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Placebo then resveratrol", 
                    "Resveratrol then placebo"
                ], 
                "description": "In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other", 
                "other_name": "Pharmaceutical grade silica"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Resveratrol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Newcastle upon Tyne", 
                    "country": "United Kingdom", 
                    "state": "Tyne and Wear", 
                    "zip": "NE1 8ST"
                }, 
                "name": "Brain performance and nutrition research centre, Northumbria university"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Trans-resveratrol on Cognitive Performance in Healthy, Young Humans: a Double-blind, Placebo-controlled, Crossover Investigation.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from the baseline to 40min post-dose scores.", 
                "measure": "Number of participants with altered cognitive function at 40mins post-dose", 
                "safety_issue": "No", 
                "time_frame": "40mins Post-dose"
            }, 
            {
                "description": "This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 2.5hr post-dose scores.", 
                "measure": "Number of participants with altered cognitive function at 2.5hrs post-dose", 
                "safety_issue": "No", 
                "time_frame": "2.5hrs post-dose"
            }, 
            {
                "description": "This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 4hr post-dose scores.", 
                "measure": "Number of participants with altered cognitive function at 4hrs post-dose", 
                "safety_issue": "No", 
                "time_frame": "4hrs post-dose"
            }, 
            {
                "description": "This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 6hr post-dose scores.", 
                "measure": "Number of participants with altered cognitive function at 6hrs post-dose", 
                "safety_issue": "No", 
                "time_frame": "6hrs post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794351"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Northumbria University", 
            "investigator_full_name": "David Kennedy", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 40mins post-dose scores.", 
                "measure": "Number of participants with altered mood at 40mins post-dose.", 
                "safety_issue": "No", 
                "time_frame": "40mins post-dose"
            }, 
            {
                "description": "This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 2.5hrs post-dose scores.", 
                "measure": "Number of participants with altered mood at 2.5hrs post-dose", 
                "safety_issue": "No", 
                "time_frame": "2.5hrs post-dose"
            }, 
            {
                "description": "This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 4hrs post-dose scores.", 
                "measure": "Number of participants with altered mood at 4hrs post-dose", 
                "safety_issue": "No", 
                "time_frame": "4hrs pos-dose"
            }, 
            {
                "description": "This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 6hrs post-dose scores.", 
                "measure": "Number of participants with altered mood at 6hrs post-dose", 
                "safety_issue": "No", 
                "time_frame": "6hrs post-dose"
            }
        ], 
        "source": "Northumbria University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Northumbria University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}